Table 2:

Baseline characteristics of the full MR CLEAN subgroups included in this study stratified by treatment

IAT (n = 78)Control (n = 121)
Mean age (yr)63 (range, 43–87)66 (range, 31–93)
Male sex (%)67 (52/78)56 (72/121)
Median NIHSS17 (IQR, 13–21)19 (IQR, 14–23)
Median ASPECTS9 (IQR, 8–10)9 (IQR, 8–10)
Diabetes mellitus (%)9 (7/78)12 (14/121)
Atrial fibrillation (%)22 (17/78)31 (37/121)
Previous stroke (%)14 (11/78)7 (9/121)
Median thrombus length (mm) (n = 186)16.2 (IQR, 11.6–22.0) (range, 4.8–39.5)15.2 (IQR, 10.3–22.3) (range, 4.8–39.5)
Median thrombus volume (mm3) (n = 186)69.3 (IQR, 51.7–111.9) (range, 6.1–329.0)70.9 (IQR, 43.8–115.5) (range, 11.4–456.7)
Median distance to thrombus (mm)6.8 (IQR, 0.0–12.8) (range, 0.0–38.2)6.4 (IQR, 0.0–13.5) (range, 0.0–38.2)
T-occlusion (%)26 (20/78)21 (26/121)
Median density thrombus NCCT (HU)49.0 (IQR, 45.2–55.2) (range, 33.1–67.8)48.9 (IQR,44.1–55.4) (range, 33.1–67.8)
Median relative density thrombus NCCT (%)137.4 (IQR, 116.0–151.4) (range, 84.8–213.0)131.2 (IQR, 117.7–151.7) (range, 65.8–274.4)
Median density thrombus CTA (HU)61.2 (IQR, 53.3–68.7) (range, 38.5–134.3)61.9 (IQR, 52.5–75.1) (range, 38.5–134.3)
Median relative density thrombus CTA (%)29.6 (IQR, 23.2–37.9) (range, 12.2–94.7)29.8 (IQR, 20.5–43.9) (range, 12.5–88.7)
Median thrombus attenuation increase (HU)12.3 (IQR, 0.74–19.6) (range, −9.9–80.0)11.2 (IQR, −0.9–28.5) (range, −9.9–80.0)
Median thrombus void fraction (%)5.8 (IQR, 0.99–12.3) (range, −8.9–61.8)6.1 (IQR, −0.47–16.8) (range, −8.9–61.8)